Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians

• DOI: 10.26442/00403660.2022.08.201523
• Publication Date: 2022-04-25T11:20:04Z
• Authors: Vladimir I. Siman...; Igor V. Maev; Olga N. Tkacheva; Sergei A. Alekseenko; Dmitry Andreev; Natalia V. Bakulina; Igor G. Bakulin; Dmitry S. Bordin; Timur D. Vlasov; Natalya M. Vorobyeva; Vladimir B. Grine...; Irina V. Gubonina; Michail Y. Drobizhev; Nikolay S. Efremov; Andrey E. Karateev; Yulia V. Kotovskaya; Iurii Kravchuk; Grigory G. Krivob...; Ekaterina V. Kulc...; Aleksander M. Lila; Marina V. Maevskaya; Anna S. Nekrasova; Elena A. Poluektova; Tatiana V. Popkova; Oleg A. Sablin; Olga I. Solovyeva; Alexander N. Suvorov; Galina N. Tarasova; Dmity I. Trukhan; Anastasia V. Fedo...
• Keywords: 0301 basic medicine; 03 medical and health sciences; Consensus; Evidence-Based Medicine; Physicians; Humans; Proton Pump Inhibitors; Bismuth

This document was produced with the support of National Medical Association for Study Comorbidities (NASС). In 2021 first multidisciplinary Consensus on pathophysiological and clinical aspects Increased Epithelial Permeability Syndrome published. The proposed guidelines are developed basis this Consensus, by same team experts. Twenty-eight Practical Guidelines Physicians statements were adopted Expert Council using "delphic" method. Such main groups epithelial protective drugs as proton pump inhibitors, bismuth probiotics discussed in these from positions evidence-based medicine. pharmacological characteristics such a universal protector rebamipide, acting at preepithelial, subepithelial levels, throughout gastrointestinal tract, presented detail.